Hantavirus in Europe 2026: The MV Hondius Outbreak Explained

When hantavirus appears in news headlines alongside country names like the Netherlands, Germany, Switzerland, and the United Kingdom, it naturally raises questions. Is there a new European epidemic? Should people across the continent be concerned? The short answer is no — but the longer answer explains why confirmed cases in multiple European countries tell a very specific story about one ship, one voyage, and one rodent-infested anchorage in the Southern Ocean.

1. Background: why Europe is involved

The MV Hondius is an expedition cruise vessel operated by Oceanwide Expeditions, a Dutch company headquartered in Vlissingen, the Netherlands. Its passengers and crew are drawn from across Europe and beyond. When an Andes virus (ANDV) outbreak occurred during a voyage that included a landing in South Georgia — a sub-Antarctic island teeming with native rodents — the infected individuals subsequently disembarked and returned home to their respective countries.

The result is a geographically dispersed cluster of cases that is epidemiologically a single event: one shipboard exposure, scattered across the residential addresses of the passengers and crew. European countries are not experiencing independent outbreaks; they are each hosting one or a small number of individuals who share a common exposure from weeks earlier.

2. Country-by-country picture (as of May 9, 2026)

The following countries have confirmed or reported cases or active contact-tracing linked to the MV Hondius cluster. Total confirmed cases across all countries stand at 14, with 3 deaths and 144 contacts under active surveillance.

Singapore has also been added to the list of affected countries as of May 9, bringing the total to 13 countries across Europe, the Americas, Africa (Saint Helena), and Asia.

3. The ECDC assessment: why general European risk is very low

The European Centre for Disease Prevention and Control (ECDC) published a Rapid Risk Assessment on May 6, 2026, and has maintained its position through subsequent updates. The assessment characterises the risk to the general European population as very low. This conclusion rests on several epidemiological realities:

• No established local transmission vector. Andes virus requires the long-tailed rice rat (Oligoryzomys longicaudatus) as its reservoir host. This rodent does not live in Europe. Without an infected rodent population, the virus has no mechanism for spreading within European ecosystems.
• Limited person-to-person transmission. While ANDV is unique among hantaviruses in its documented capacity for human-to-human spread, this transmission requires close, prolonged contact — typically household exposure. It is not airborne in the ordinary sense and does not spread through casual community contact.
• Contained source population. The universe of people at risk is, by definition, limited to those who were on board the MV Hondius during the affected voyage and their closest contacts. This is a finite, identifiable group — not an open community transmission chain.
• Rapid identification and tracing. Contact tracing expanded from 30 contacts on May 4 to 144 by May 9. Health authorities in all affected countries have been able to identify, locate, and place under active surveillance the individuals at risk.

The ECDC recommends continued surveillance of identified contacts and asks clinicians to consider hantavirus in the differential when evaluating unexplained fever or respiratory illness in a patient with plausible travel history.

4. How European health systems have responded

The coordination across European countries has been notable for its speed. Key response actions include:

• ECDC acting as a central hub for cross-border information sharing under the International Health Regulations framework.
• National reference laboratories — including those in the Netherlands, Germany, and the UK — confirming diagnoses by RT-PCR and serology, allowing rapid classification of suspected cases.
• WHO Director-General travelling to Tenerife in early May to coordinate the disembarkation of remaining MV Hondius passengers, signalling the seriousness with which international agencies are treating the cluster.
• Clinical advisories issued by national bodies (RIVM, RKI, UKHSA, Santé publique France) alerting emergency physicians and infectiologists to ask about cruise-ship travel in febrile patients.

5. Historical context: has hantavirus appeared in Europe before?

Yes — but not in this form. Europe has its own endemic hantaviruses, primarily Puumala virus (carried by the bank vole) in Scandinavia, Finland, Germany, France, and Belgium, and Dobrava virus in the Balkans. These cause Hemorrhagic Fever with Renal Syndrome (HFRS), a different clinical entity from the Hantavirus Pulmonary Syndrome (HPS) caused by Andes virus.

Puumala-associated HFRS is actually fairly common in epidemic years in Finland and Sweden, with hundreds or occasionally thousands of cases reported. It is generally milder than Andes-virus HPS, with a case fatality ratio well below 1% in most series.

The 2026 MV Hondius cluster is therefore unusual not because hantavirus is new to Europe, but because it involves an imported, more lethal strain with person-to-person transmission potential, distributed across multiple countries simultaneously.

6. What this means for European travellers to South America

The MV Hondius outbreak does not change the general risk profile for European travellers to South America dramatically — ANDV has always been present in Patagonia and other parts of southern Chile and Argentina. What it has done is sharpen awareness among European clinicians and public-health authorities of a disease that previously received little attention in European medical education.

Travellers to Patagonia, southern Chile, or Argentina should be aware of hantavirus risk and take standard precautions: avoid contact with wild rodents, do not disturb rodent nests or burrows, and ventilate enclosed spaces before entering. There is currently no licensed vaccine for Andes virus.

For detailed travel risk information, see the Patagonia travel risk guide. For the full outbreak timeline, see the MV Hondius outbreak tracker.

7. Frequently asked questions

If I live in a country with confirmed cases, am I at risk?

Not unless you were on board the MV Hondius or are a close household contact of a confirmed case. The presence of a case in your country does not create community transmission risk, because there is no local rodent reservoir and person-to-person spread requires prolonged close contact.

Should European clinicians start testing for hantavirus broadly?

No. Testing should be reserved for patients with compatible symptoms and a plausible exposure history. Broad reflexive testing of febrile patients would generate false positives, consume laboratory capacity, and create unnecessary alarm. The clinical advisory issued in most affected countries specifically targets patients with cruise-ship travel to sub-Antarctic regions or with known contact with a confirmed case.

How is this different from an epidemic?

An epidemic involves sustained transmission within a population — each generation of cases producing the next. The MV Hondius cluster is a common-source outbreak: all cases trace back to a single exposure event. Once that exposure cohort has been fully identified and monitored through the incubation window, the outbreak ends. There is no epidemic curve extending into the future; there is a defined group of people who need to be watched for approximately six weeks.